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Abstract
Despite its long-standing status as the diagnostic “gold standard”, the renal transplant biopsy is limited by a
fundamental dependence on descriptive, empirically-derived consensus classification. The recent shift towards
personalized medicine has resulted in an increased demand for precise, mechanism-based diagnoses, which is not
fully met by the contemporary transplantation pathology standard of care. The expectation is that molecular
techniques will provide novel pathogenetic insights that will allow for the identification of more accurate diagnostic,
prognostic, and therapeutic targets. Here we review the current state of molecular renal transplantation pathology.
Despite significant research activity and progress within the field, routine adoption of clinical molecular testing has not
yet been achieved. The recent development of novel molecular platforms suitable for use with formalin-fixed
paraffin-embedded tissue will offer potential solution for the major barriers to implementation. The recent
incorporation of molecular diagnostic criteria into the 2013 Banff classification is a reflection of progress made and
future directions in the area of molecular transplantation pathology. Transcripts related to endothelial injury and NK cell
activation have consistently been shown to be associated with antibody-mediated rejection. Prospective multicenter
validation and implementation of molecular diagnostics for major entities remains an unmet clinical need in
transplantation. It is expected that an integrated system of transplantation pathology diagnosis comprising molecular,
morphological, serological, and clinical variables will ultimately provide the greatest diagnostic precision.
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Introduction
Despite its limitations, the renal transplant biopsy still
represents the diagnostic “gold standard” [1]. Its diag-
nostic precision is limited by the fact that assessment is
mostly based on descriptive, empirically-derived consen-
sus classifications that frequently lack an etiologic basis
[2]. This approach is becoming increasingly insufficient
in the era of personalized medicine, in which precise,
mechanism-based diagnoses are the prerequisite for tar-
geted treatment in the individual patient [3, 4]. The ex-
pectation is that molecular technologies will provide
novel insights into disease mechanisms and thus allow
for the identification of more accurate diagnostic, prog-
nostic, and theranostic (i.e., predicting response to tar-
geted treatment) biomarkers. Although significant
progress and insights have been derived from molecular
studies, widespread adoption of molecular diagnostics in
renal transplantation pathology has not yet been
accomplished. Further validation of specific applications
leading to increased diagnostic precision in a clinically
relevant setting is ongoing.
To date, the majority of the comprehensive data sets
that include clinicopathological correlations have been
derived from quantitative transcriptomics analysis of
renal transplant biopsies and, to a lesser degree, urine
and blood [5–11]. Despite this, urine provides a poten-
tially unique, non-invasive window on the kidney, espe-
cially for those molecules that ‘leak’ into the urine in
association with tubular injury [12–14]. The main focus
for molecular diagnostic research in renal allografts was
on rejection (T cell mediated and antibody-mediated)
and the assessment of acute tissue injury, especially in
the context of predicting organ function immediately
post transplantation and late allograft failure [11, 15, 16].
Limited research data are available for assessing the mo-
lecular phenotype of relevant differential diagnosis like
drug toxicity, in particular Calcineurin inhibitor nephro-
toxicity, and viral or other infections in the allograft. Ac-
cordingly, we will focus here on reviewing the clinical
value of integrating molecular assessments of rejection
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and acute allograft injury with standard histopathology
assessment of renal allograft biopsies.
For most molecular platforms, extra biopsy material
needs to be specifically procured and stabilized, poten-
tially representing additional risk and inconvenience for
the patient [17, 18]. However, high-throughput gene ex-
pression platforms that work with formalin-fixed,
paraffin-embedded (FFPE) samples have recently be-
come available. For example, the NanoString nCounter®
Analysis System (Seattle, WA) is a molecular “barcode”
probe-based technology that enables direct, digital quan-
tification of nucleic acids without amplification, using
low amounts of short fragments of total RNA, miRNA,
or DNA [19]. The nCounter® system is highly multi-
plexed, with the capacity of quantifying up to 800 targets
simultaneously, and has been shown to be more sensi-
tive than microarrays and similar in sensitivity to real-
time PCR [19, 20]. Platforms like this have the potential
to enable translation of multi-parametric molecular sig-
natures from omics discovery studies into clinical FFPE
diagnostics using the same sample that is reviewed
under the microscope. This would allow for practical in-
tegration of molecular diagnostics into the current
standard of care. Furthermore, the ability to apply mo-
lecular quantification techniques to FFPE samples intro-
duces the possibility of conducting large retrospective
validation studies for new molecular diagnostics on well
annotated samples with long-term follow-up.
Beyond the light microscope: molecular assessment of
donor biopsies
Organ donation and especially brain death induces a sig-
nificant molecular response in donor tissue [21, 22].
Qualitative assessment of a donor organ, with the aim of
guiding allocation and post-transplantation management
to achieve the best possible function and outcome in the
recipient, represents a major unmet clinical need. Nu-
merous histological, clinical, and combined scoring and
assessment systems for donor organs have been de-
scribed, but a significant proportion of harvested donor
kidneys is still discarded without robust evidence.
At the transcriptional level, the response to tissue in-
jury presents as a reduction in the expression of genes
related to cell transport and an up-regulation of cell
cycle, repair and tissue remodelling transcripts along
with embryonic pathways like wnt and notch [23, 24]. In
addition, genes associated with immune, signal transduc-
tion, and oxidative stress responses have been shown to
be increased in donor biopsies from recipients with im-
paired function post-transplantation [25]. The mRNA
expression of well-known acute kidney injury (AKI) bio-
markers like LCN2 and HAVCR1/KIM-1 has been found
to be significantly increased in recipients developing de-
layed graft function (DGF) [26]. In microarray studies of
time-zero biopsies taken post-reperfusion, unsupervised
analysis separated donor kidneys into three groups: liv-
ing donors, low-risk deceased donors, and high-risk de-
ceased donors who demonstrated the greatest incidence
of DGF [21]. The strongest correlate with early dysfunc-
tion in the high-risk donors was mean expression of a
set of 30 injury transcripts. These included well-known
biomarkers of AKI primarily expressed by tubular epi-
thelial cells like osteopontin M receptor, integrin β6,
lipocalin 2, versican, cathepsin S, and cadherin 6 [27].
Molecular assessment of donor biopsies therefore has
the potential to quantify tissue injury and identify organs
at risk for DGF. This can guide the development of spe-
cific post-transplant strategies for these high-risk donor
organs and consequently reduce current discard rates.
Beyond the light microscope: molecular diagnosis of T
Cell-Mediated Rejection (TCMR)
Numerous studies have described the molecular pheno-
type of renal allograft biopsies presenting with the char-
acteristic histological features of TCMR (i.e., interstitial
infiltration and tubulitis): transcripts expressed by sub-
sets of T lymphocytes (cytotoxic T lymphocytes (CTLs),
effector memory T cells, T helper cells, regulatory T cells
[28–31]), transcripts expressed by macrophages [32, 33],
and transcripts regulated by interferon-gamma (IFNγ)
[34, 35]. These include prototypical CTL transcripts like
granzyme B, perforin, and Fas ligand [10, 18, 36–41]. In-
cluded among the numerous IFNγ-regulated cytokines
and chemokines associated with acute rejection were
TGFβ, TNFα, RANTES, MIP-1α, HLA class I and II
molecules, CXCL9, CXCL10, and CXCL11 [10, 42, 43].
Genome-wide microarray discovery studies confirmed
earlier hypothesis-based PCR studies and revealed that
numerous transcripts show similar expression patterns
under the same disease condition [5, 15, 43, 44]. Sarwal
and colleagues were the first to apply genome-wide mi-
croarrays for systematic screening of genes expressed in
rejecting grafts. This study confirmed the expression of
T cell transcripts, but also found a B cell signature asso-
ciated with subsequent graft failure [9].
Hundreds of individual members in the described sets
of genes associated with TCMR change their expression in
a highly correlated, stereotyped fashion, moving in large
groups that reflect the major biological processes operat-
ing in renal allografts [11, 15, 43]. This observation was
recently expanded upon in a comprehensive meta-analysis
of human gene expression studies in allo graft rejection
across all organ types [45]. The authors postulate an “Im-
munological Constant of Rejection” hypothesis based on
the observation that different immune-mediated processes
(i.e., allograft rejection, autoimmunity, infection, cancer,
graft-versus-host disease, acute cardiovascular events,
chronic-obstructive pulmonary diseases, and placental
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villitis) share common convergent final molecular mecha-
nisms. Molecular features consistently described in these
different immune- mediated tissue destruction processes
include the activation of IFNγ-regulated genes, the re-
cruitment of cytotoxic cells through massive production
of respective chemokine ligands (primarily through
CXCR3/CCR5 ligand pathways), and the activation of im-
mune effector function genes (i.e., genes expressed by
CD8-positive cytotoxic T cells and NK cells upon activa-
tion) [45].
Accordingly, the Edmonton group used their com-
prehensive collection of human renal allograft biopsy
mRNA microarray data to build an unsupervised pre-
dictive TCMR classifier [42, 46]. This classifier sum-
marizes the molecular groups of the fundamental
immune-pathological mechanisms of rejection and as-
signs a percent probability score to each individual bi-
opsy indicating the likelihood of TCMR based on its
genome-wide molecular phenotype. Using such a clas-
sifier, molecular diagnostic thresholds for TCMR can
be defined and potentially used for clinical decision
making.
Beyond the light microscope: molecular diagnosis of
Antibody-Mediated Rejection (ABMR)
In 2013, the international Banff classification for allo-
graft rejection underwent significant revision and now
includes molecular assessment of antibody-mediated in-
jury as a potential diagnostic criterion for ABMR inde-
pendent of C4d staining [47]. Over the last several years,
considerable evidence has emerged that previous Banff
criteria for ABMR, due to its dependence on C4d,
missed a significant proportion of ABMR cases. In paral-
lel, underlying mechanisms of antibody-mediated tissue
injury have become increasingly better understood [48].
In the vast majority of ABMR, anti-HLA antibodies
find their target in the microcirculation of the allograft.
This interaction between antibodies and the endothelial
cell causes stress to the microcirculation, mediated
through classical complement activation, direct inter-
action of the antibody with the endothelium, or cell-
dependent cytotoxicity via Fc receptors on neutrophils,
NK cells, or macrophages [49]. Such interactions be-
tween antibody and antigen lead to significant molecular
changes in the endothelium of the kidney allograft
microcirculation (i.e., peritubular capillaries and glom-
eruli). Sis et al. were the first to develop a literature-
based set of transcripts with expression restricted to
endothelial cells [50]. The authors found a significant
up-regulation of endothelium-specific molecules, such as
factor VIII / von Willebrand factor (VWF), melanoma
cell adhesion molecule (MCAM/CD146), cadherin-5
(CDH5), selectin E (SELE/CD62E), platelet/endothelial
cell adhesion molecule 1 (PECAM1/CD31), CD34,
caveolin 1 (CAV1), in human renal allograft biopsies
with histological features of antibody-mediated tissue in-
jury and simultaneous presence of donor-specific anti-
bodies (DSA).
Subsequently, as the correlate of antibody-facilitated
cell-dependent cytotoxicity, molecules specific for NK
cell infiltration were shown to be associated with micro-
circulation inflammation (i.e., capillaritis and glomeruli-
tis) and the presence of DSA [51, 52]. By comparing the
intragraft gene expression between patients with and
without DSA, the following NK cell specific transcripts
were found to be increased in biopsies from DSA-
positive patients: fractalkine receptor (CX3CR1), myelo-
blastosis viral oncogene homolog-like 1 (MYBL1), fibro-
blast growth factor binding protein 2 (FGFBP2, also
known as KSP37), killer cell lectin-like receptor F1
(KLRF1, also known as NKp80) and SH2 domain con-
taining 1B (SH2D1B, also known as EAT2). In cases with
ABMR pathology and the presence of DSA, expression
of both endothelial and NK cell transcripts was inde-
pendent of C4d staining results, with up to 60 % being
C4d-negative.
Several groups have since independently confirmed
these mechanistically derived associations between
ABMR and endothelial, NK cell, and inflammatory
transcripts. The Mayo group studied the intragraft
gene expression profiles of positive crossmatch (+XM)
kidney transplant recipients who do and do not de-
velop transplant glomerulopathy (TG). Comparison of
protocol renal allograft biopsies in + XM/TG+ and
control groups revealed significantly altered expres-
sion in up to 3200 genes, including inflammatory, NK
cell, and endothelial cell transcripts [53]. Similarly,
colleagues from the Montefiore Medical Center, New
York demonstrated differential intragraft gene expres-
sion profiles between patients with TG and graft loss
and those with TG and functioning grafts. Endothelial
transcripts, complement-associated transcripts, inter-
leukins, and granulysin (CTL-associated) were signifi-
cantly up-regulated in biopsies from the TG group
with consecutive graft loss [54]. In addition, the same
group demonstrated increased expression of gene
transcripts related to CTLs, NK cells, macrophages,
and IFNγ in both cases with DSA-positive/C4d-posi-
tive chronic ABMR and DSA-positive/C4d-negative
TG, providing further evidence that DSA-positive TG
represents true ABMR despite being negative for C4d
[55, 56]. Independently, a microarray-based classifier
was developed that assigned diagnostic ABMR prob-
ability scores to each biopsy. The transcripts distin-
guishing ABMR from other diagnoses were again
mostly expressed in endothelial or NK cells or were
IFNγ-inducible. The classifier scores correlated with
the presence of microcirculation injury according to
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Banff lesion scores and DSA levels [57]. The fact that
this classifier independently uses endothelial and NK
cell-associated transcripts for diagnosing ABMR fur-
ther corroborates the above described hypothesis-
driven observations by others that such transcripts
are specifically increased in renal allografts with
ABMR.
These findings indicate that molecular studies, par-
ticularly with endothelial gene sets, can be used to
measure ongoing ABMR activity leading to TG, which
is associated with eventual progression to graft failure.
Therefore, adding quantitative molecular assessments
to the Banff classification for DSA-positive cases has
the potential to increase diagnostic precision for C4d-
negative antibody-mediated rejection.
Beyond the light microscope: molecular prediction of
allograft outcome
A molecular classifier for the prediction of allograft fail-
ure in clinically-indicated biopsies taken more than one
year post-transplantation was described as being super-
ior to all known clinical (creatinine, proteinuria, GFR)
and morphological risk factors (Banff lesion scores and
diagnoses) for allograft failure. Interestingly, the classifier
utilized genes included in the acute molecular AKI re-
sponse as the main source for prediction. This suggests
that an ongoing active molecular injury response in the
tissue, due to progressive diseases like rejection or glom-
erular diseases, is the main correlate for functional de-
terioration in late allograft biopsies [58]. Increased
expression of acute injury response genes correlated
Fig. 1 Overlap in main molecular - histopathological - clinical phenotypes in kidney allografts: The molecular phenotype in renal allografts
presents as changes in groups / sets of genes/transcripts which are strongly correlated with each other. Few “top” genes can be selected to
represent specific biological processes like T cell infiltration and activation. These molecular phenotypes correlate with related histological lesions
and other serological parameters, e.g., microcirculation inflammation and DSA with increased expression of endothelial and NK cell genes in
antibody-mediated rejection. Of note is that to some extent the different molecular phenotypes overlap between diagnostic entities and thus
cannot be considered absolutely specific, i.e., similar to non-specific histological lesions
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with poor function and with inflammation in areas of fi-
brosis, but not with fibrosis without inflammation [59].
Many individual transcripts expressed in late biopsies
from failing allografts were shared between the acute in-
jury gene set [24, 59] and the molecular risk score de-
rived from the predictive allograft survival classifier,
including integrin β6 (ITGB6), versican (VCAN), and
nicotinamide N-methyltransferase (NNMT). Therefore,
at a molecular level, progression to failure is primarily a
function of ongoing parenchymal injury caused by vari-
ous specific diseases like recurring glomerulonephritis or
ABMR.
Conclusions
The results obtained from genome-wide expression
studies in kidney transplant biopsies indicate that the
vast majority of differentially expressed molecules rep-
resent a stereotyped tissue response to injury caused
by and overlapping between different disease processes.
However, within this non-specific injury and inflamma-
tion response, identification of patterns correlating
with disease activity and prognosis can allow for
disease-specific information to be elucidated (Fig. 1).
Finding diagnostic specificity in large-scale molecular
changes is as challenging as with non-specific morpho-
logical features like interstitial inflammation or tubular
atrophy, which as well overlap between disease entities.
It is unlikely that even the most comprehensive mo-
lecular assessments will provide absolute diagnostic
precision. Although molecular assessment may be su-
perior in some settings such as early tissue injury,
which is essentially invisible to morphology, histopath-
ology will always carry greater specificity and sensitiv-
ity in other entities like focal glomerular diseases.
Therefore, a process for consensus generation will be
needed to adopt molecular diagnostics (including re-
lated biostatistical algorithms) as it was the case for
histopathological diagnostic criteria through the Banff
process [2]. Given that relative small sets of genes can
provide measurements of relevant aspects of different
disease processes, consensus is needed in regard to
which genes should be measured and which thresholds
should be considered diagnostically and clinically rele-
vant. But, deriving a diagnostic molecular signature
and relevant diagnostic thresholds from large-scale,
high-dimensional omics data is a major challenge in
the absence of a true diagnostic gold standard for
training and validation purposes. This is the case with
transplantation pathology in that the Banff classifica-
tion system is empirically-derived and consensus-based
but not necessarily representative of true pathogenetic
and biological disease mechanisms [2].
It is therefore likely that an integrated diagnostic sys-
tem comprising molecular, morphological, serological,
and clinical variables, as proposed in the revised 2013
Banff classification, will provide the greatest diagnostic
precision [47]. The adoption of such a refined, integrated
diagnostic system into clinical practice will require on-
going interdisciplinary multicenter efforts for conducting
well-designed validation studies. With the recent avail-
ability of novel molecular technologies and user-friendly
biostatistics tools, these studies can now be conducted
both retrospectively and prospectively. This provides the
opportunity for robust outcome-based validation of mo-
lecular diagnostics independent of current arbitrary
histology-based diagnostic consensus.
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